GlaxoSmithKline Presents New Data for Nucala (mepolizumab) from REALITI-A Interim Analysis

GlaxoSmithKline plc (GSK) presented new data for Nucala (mepolizumab) from an interim analysis of REALITI-A, the first prospective global real-world study of a biologic treatment in patients with severe eosinophilic asthma. Results show a significant reduction in exacerbations and oral corticosteroid (OCS) use in patients after one year of treatment with Nucala when taken in a routine care setting, compared to the prior 12 months.

Christopher Corsico, Senior Vice President Development, GSK, said: “Exacerbations can be devastating for people living with severe eosinophilic asthma. The interim results from REALITI-A continue to demonstrate Nucala effectively reduces exacerbations, this time in a routine care setting. We look forward to sharing the full results from this study after it completes in 2021.”

REALITI-A is a two year, global, prospective, single-arm, observational study of patients with severe eosinophilic asthma newly prescribed Nucala and is being conducted in a routine care setting. The interim analysis of 368 patients presented at the 2019 European Respiratory Society (ERS) International Congress showed that, compared to the prior 12 months, after a year of treatment there was a:

  • 69% reduction in the annual rate of clinically significant exacerbations (RR 0.31; 95% CI 0.27, 0.35), the primary endpoint of the study.
  • 77% reduction in the annual rate of exacerbations requiring hospitalisation/emergency room visits (RR 0.23; 95% CI 0.18, 0.30).
  • Reduction in median OCS dose (n=159) from 10 mg/day to 5mg/day, with 34% of patients (49/143) able to stop OCS completely.

Study investigator, Professor Tim Harrison, University of Nottingham and Nottingham University Hospitals NHS Trust, UK added: “Real-world studies like REALITI-A enhance our understanding of the beneficial effects medicines can make over and above data from randomised controlled trials. REALITI-A included a wider range of patients with severe asthma, studied in a setting that more closely resembles their everyday lives. Severe eosinophilic asthma can have a devastating impact on patients’ quality of life, so to see the interim analysis show patients benefitting from treatment with mepolizumab after a year is encouraging and mirrors my personal experience with using mepolizumab. I look forward to seeing the full results.”

Safety data from the study were consistent with results from previous clinical trials. 14% (53/368) of patients had on-treatment adverse events, with the most common being headache (23/368), nausea (5/368), fatigue (4/368), influenza like illness (4/368), back pain (3/368) and myalgia (3/368) and <1% (2/368) had on-treatment serious adverse events. There were no deaths.

REALITI-A is expected to complete in 2021 and full results will be published and presented at future scientific meetings in due course.



Related Topics and Keywords

Subscribe to our FREE newsletter

We will not sell or give your information to a third party. See our Privacy Policy